Introduction
Acute myeloid leukemia (AML) is a heterogeneous group of malignancy. Although the survival of AML patients has been significantly prolonged by recent advances in supportive care and disease-specific treatment, the cure rate of this disease remains low. 1 Most patients who achieve a complete remission (CR) after chemotherapy relapse and die of the disease. The criteria of CR are conventionally based on the clinical and cytomorphological observations. However, microscopic examination has low sensitivity in detecting minimal residual disease (MRD). Recently, the International Working Group included molecular remission as one of the criteria for treatment response in AML 2 The detection of MRD in AML by quantitative polymerase chain reaction (PCR) of abnormal fusion transcripts was found to be of high prognostic value. [3] [4] [5] However, the molecular detection of MRD in AML is mainly restricted to patients with specific chromosomal translocations/ fusion genes, such as t(8;21)/AML1-ETO, t(15;17)/PML-RARa and inv(16)/CBFB-MYH11. For those with a normal karyotype, numerical aberrations or random structural abnormalities, the application of PCR-based MRD detection was not possible. Though FLT3 internal tandem duplication can be detected in about 20% of all AML patients, it is not stable during the course of the disease 6 and thus not a good marker for MRD detection. A transcriptional repressor encoded by Wilms' tumor gene (WT1) is overexpressed in AML patients and has been used as a PCR target to detect MRD, but the sensitivity is approximately two orders of magnitude lower than that of fusion genes and the results concerning clinical implications of WT1 transcript published in literature are discrepant to each other. 7, 8 Searching for a feasible marker for MRD monitoring in AML patients with mutations other than aberrant fusion genes is warranted.
Recently, a ground-breaking work by Falini et al. 9 revealed Nucleophosmin (NPM1) mutations in AML patients, especially in those with a normal karyotype. Their findings were subsequently confirmed in thousands of AML patients by other studies. [10] [11] [12] [13] [14] [15] [16] [17] [18] The mutation invariably occurred as a tetranucleotide insertion at the C terminal part of the transcript. In addition, the mutation showed a great stability during disease evolution. 15 We thus predict NPM1 mutation can be an ideal and useful marker for MRD detection based on the high prevalence, the great stability and the fixed pattern of mutations. Very recently, NPM1 mutant was used as a marker for quantification of MRD in AML patients bearing mutations of this gene. 19 However, the number of patients studied in that report was limited and the follow-up time was rather short. It is not clear whether MRD monitoring by this technique has any prognostic significance.
Here, we presented an independently developed system for absolute quantification of MRD in 194 samples from 38 AML patients bearing NPM1 mutations with a follow-up period spanning over nearly 10 years. We found that NPM1 mutant copies correlated with disease status and that absolute quantification of NPM1 mutants allowed identification of patients with a higher risk of relapse and shorter survival.
Materials and methods

Patients
Patients of de novo AML were screened for NPM1 mutations by direct sequencing on PCR products. 9, 15 The informed consents were obtained from the patients, and the study has obtained agreement from the Internal Review Board from the National Taiwan University Hospital.
Cell harvest, DNA extraction and mutation analysis Bone marrow (BM) cells were collected as described previously. 15 We routinely sampled BM about 1 month after induction and within 3 months after consolidation, depending on the general conditions of the patients, but some samples were not available at the time of this study. Hence, the intervals of tested samples were not homogeneous. Analysis of NPM1 exon 12 mutation was performed as described previously. 9, 15 Detection of internal tandem duplication of FLT3 (FLT3/ITD) was performed as described previously. 20 The PCR products were purified and directly cloned into pGEM-T or pGEM-T-EASY vector as instructed by the manufacturer (Promega, Madison, WI, USA). The plasmids were sequenced and the wild-type (WT) and mutant clones were used for standard curves in subsequent real-time PCR.
Quantitative real-time PCR (qPCR) was performed with universal PCR master mix (Applied Biosystems, Foster City, CA, USA). In every 20 ml of reaction mixture, there were 10 ml of 2 Â master mix, 500 nM each primer, 250 nM carboxyfluorescein (FAM)/minor groove binding protein (MGB)-labeled probe and 200 ng genomic DNA. The reaction was performed on 7700 or 7300 sequence detection system (Applied Biosystems, Foster City, CA, USA), comprising 501C for 2 min, 951C for 10 min, followed by 45 cycles of 951C for 15 s and 601C for 1 min. The sequences of the common forward primer, probe and the mutation-specific reverse primers were listed in Figure 1 .
Every sample was tested at least twice independently. If there is a 41.0 of discrepancy in cycle of threshold (C t ) value between these two runs, a third test is mandatory. The NPM1 mutant copies were quantified only at successful amplification of internal control (INC).
Statistics w
2 -test was employed to calculate the significance of association between the increment of NPM1 mutant copies during followup and subsequent clinical relapse. The mutant copy numbers at various disease statuses were compared by paired t-test. Nonparametric Mann-Whitney U-test was used to calculate the difference between non-paired samples. Kaplan-Meier curve was calculated by SPSS software (Chicago, IL, USA).
Results
Detection of MRD by qPCR
A total of 38 AML patients bearing NPM1 mutations were analyzed. All were newly diagnosed patients with de novo AML. This was a retrospective study. Therefore, some variation of treatment existed among the patients, but all the patients received anthracycline plus cytarabine as an induction therapy. Subsequent consolidation treatment included high-dose cytar- abine with or without anthracycline. Ten patients received hematopoietic stem cell transplantation from sibling donors; one of them had a prior autologous transplant. The detailed clinical data are shown in Table 1 and Supplementary Figure. There were seven different mutations detected; all occurred as an insertion of four nucleotides at the C terminal part of NPM1 transcript (reference sequence GenBank accession number NM_002520) ( Figure 1a ). We designed mutant-specific reverse primers, with the FAM/MGB probe and the forward primer common to WT and all the mutant alleles (Figure 1b and c).
Using another reverse primer 3 0 to the mutation area, with the same probe and forward primer, the PCR product could serve as an INC. Both wild and mutated NPM1 alleles could be amplified with this pair of primers. Therefore, the copies of the internal control gene quantified in this manner reflected the total cells in the samples no matter they were leukemic or normal cells. This design basically is identical to the report from Gorella et al.,
19 who used Albumin gene as an internal control. For absolute quantification of NPM1 mutants, we used cloned plasmids containing either WT or mutant NPM1 sequences to generate standard curves of INC and mutants, respectively. We diluted each of the seven mutants serially from 10 6 to 10 copies per reaction and found as low as 10 copies of all mutants could be reliably detected, with an amplification efficiency about 90% and a slope of standard curves À3.481 (Figure 2a) .
We used BM genomic DNA without NPM1 mutations to serially dilute the genomic DNA obtained from NPM1-mutated patients at diagnosis, and found that the sensitivity of our method could reach 10
À5
, with a good correlation between the C t values and dilution fold (Figure 2b ). The specificity of this system was ascertained by absence of mutant signals using 200 ng of genomic DNA without NPM1 mutation and from three cell lines, U937, TUR (both were AML cell lines) and HeLa, all of which did not harbor NPM1 mutations as confirmed by DNA sequencing (data not shown).
Correlation of absolute quantities of NPM1 mutants with disease statuses
We then applied this system to monitor 194 samples from 38 AML patients with NPM1 mutations (mean five samples per patient), with a median follow-up time of 20.6. months (range 2.5-113.5). The first post-induction samples were taken at a Table 1 The clinical data of patients in this study Figure 3 .
The mutant copies in all patients at diagnosis were homogeneous, with a median of 117 000 for every 100 000 copies of INC (endogenous NPM1 gene amplified by primers common to both wild and mutant alleles shown above, with 200 ng genomic DNA in every reaction). Induction chemotherapy reduced leukemia cells by 0-5.21 logs, with a median reduction of 2.78 logs (Po0.001, Figure 4a ). On the other hand, all clinical relapses were accompanied by a rise of mutant copy numbers, with a median increase of 2.76 logs (range 0.38-5.54, Po0.001 by paired t-test, Figure 4b ). The correlation between the marrow blast percentage and the mutant copy numbers is shown in Figure 4c . Obvious increase of blasts in BM was invariably correlated with high-copy numbers, but frequently, low percentage of BM blasts could be associated with high mutant copies (false negative by cytomorphology), perhaps because many morphologically normal cells were in fact leukemia cells. All samples with absence of NPM1 mutants by qPCR showed normal percentages of BM blasts with the exception of five samples in which blast percentages were increased by morphology. The increased blast cells in these five samples might represent regenerating normal hematopoietic progenitors in the recovery stage of BM after chemotherapy.
Clinical implications of qPCR monitoring of NPM1 mutants during follow-up
Among the 38 patients, 37 obtained a CR. Two of them died of complications when in CR (Patients no. 14 and 15 in Group 3, Supplementary Figure 1 ), 13 were alive and remained in continuous CR (CCR, Group 1, Supplementary Figure 1) , and the remaining 22 relapsed (Group 2, Supplementary Figure 1) . After achieving CR, the mutant copy numbers in the patients with subsequent clinical relapse were significantly higher than those remaining in CCR (mean copy numbers 7200 vs301 per 100 000 copies of INC, Po0.001 by Mann-Whitney U-test). In the 13 patients with CCR, seven had persistent absence of NPM1 mutant in 2-5 (median 4) follow-up samples after treatment, four (Patients no. 17, 30, 34, 35) were free of detectable signal in the last BM samples, and the remaining two patients (no. 11, 16) had transiently detectable mutant in only one sample. On the contrary, in the 22 patients with relapse (Group 2 in Supplementary Figure 1) , all showed either persistently detectable NPM1 mutants before the first relapse (R1) (15 patients: no. Figure 1) .
Furthermore, the patients with any rise of mutant signals along serial follow-up had 3.2-fold increase of relapse risk, compared to the patients with persistently low or undetectable mutants (86 vs 27%, Po0.001). The patients who failed to obtain a reduction of mutant copy number to less than 0.1% of INC (n ¼ 7, Patients no. 4, 19, 21, 24, 25, 29, 38, Supplementary Figure 1 ) had significantly shorter overall survival (OS) and relapse-free survival (RFS) than the other 31 patients, with a median of 11.3 months vs 57.9 months (P ¼ 0.004, Figure 5a ) and 4.0 months vs 18.6 months (Po0.001, Figure 5b ), respectively.
After induction chemotherapy, the extent of reduction in mutant copies had no implication on the RFS or OS (data not shown). However, among the 22 patients who had samples obtained within 6 months after consolidation chemotherapy, those who could not achieve reduction of mutant copies by at least 2 logs after consolidation chemotherapy (n ¼ 6, Patients No. 19, 24, 27, 29, 32, 36) had a shorter median OS (11.3 months vs not reached, P ¼ 0.010, Figure 6a ) and RFS (3.8 months vs 21.2 months, P ¼ 0.001, Figure 6b) 
Impact of FLT3/ITD in survival and reduction of NPM1 mutants after treatment
In these 38 patients with NPM1 mutations, 13 also harbored FLT3/ITD. The other 25 NPM1-mutated but FLT3/ITD-negative patients had significantly better RFS and a trend of better OS (P ¼ 0.015 and P ¼ 0.066, respectively, data not shown), confirming the findings of the previous studies. 10, 13, 14, 18 Moreover, this group of patients had an obvious trend of higher chance to obtain at least one complete molecular remission, compared with the other group of patients with FLT3/ITD (P ¼ 0.056). A larger cohort of patients is needed to confirm the impact of FLT3/ITD in NPM1 mutant reduction after treatment.
Discussion
NPM1 mutation has proved to be one of the most common mutations in AML, a finding initially reported by Falini et al. and subsequently confirmed by others. [10] [11] [12] [13] [14] [15] 18 The great stability of the mutation during disease evolution and its close associa- Figure 4 The correlation between the mutant copy numbers and disease statuses (a and b) and BM blast percentages (c). The amount of mutants correlated well with disease statuses. Obvious increase of blasts in BM was invariably correlated with large amount of mutant copies, but frequently low percentage of BM blasts could be associated with high mutant copies (false negative by cytomorphology).
tion with disease status suggest a role of this mutation in monitoring MRD. 15 During preparation of this paper, Gorello et al. 19 reported the application of NPM1 mutation as a marker for MRD detection. Because the number of patients studied in that report was limited and the follow-up time was short, the prognostic implication of MRD in AML patients with NPM1 mutation remains to be determined. In this retrospective study, we tried to validate the utility of NPM1 mutant quantification in MRD monitoring and outcome prediction based on the extractable and objective data. We focused on the parameters which would not be significantly compromised by the irregularity of marrow sampling in this study.
Using an independently developed qPCR method, we could detect NPM1 mutants sensitively and specifically. Monitoring NPM1 mutant by this technique is very valuable in predicting prognosis. Samples taken at the first morphological CR from the patients with subsequent clinical relapse contained more mutant copies than those from the patients without subsequent relapse. Along serial follow-up, the patients who could achieve a reduction of NPM1 mutant copy number to lower than 0.1% of INC had a longer OS and lower risk of relapse than those who could not ( Figure 5 ). These parameters can thus serve as predictors of the outcome of AML patients with NPM1 mutations in a prospective and real-time manner in clinical patient care. Probably due to high sensitivity of drug-naive leukemia cells to chemotherapy, most patients experienced dramatic reduction of tumor burden after induction treatment in our series (data not shown). Hence, the extent of reduction of mutants after induction treatment did not have significant impact on RFS and OS. But the MRD after the consolidation chemotherapy showed prognostic significance ( Figure 6 ). Moreover, most patients with persistent absence of NPM1 mutant after consolidation chemotherapy remained in CCR (Figure 3 and Group 1 in Supplementary Figure 1 ), whereas those with persistently detectable mutant or only temporary disappearance of the signal relapsed subsequently (Group 2 in Supplementary  Figure 1 ). In addition, any rise of NPM1 copy number during the follow-up period predicted high risk of relapse. Because this was a retrospective study, BM samples were not collected regularly. However, with the long median follow-up time (20.6 months) and a mean of five samples per patients analyzed, our data suggested that qPCR of NPM1 mutants might have prognostic implications. Further prospective studies are warranted to confirm these findings. The maximal sensitivity of qPCR reported by Gorello et al.
19
was around 10 À4 -10 À5 . The sensitivity in our current report seems a little higher, reaching 10 À5 . One possible reason is the difference in amount of DNA for the serial dilution. It is possible that less amount of mutant DNA or larger amount of background WT DNA might interfere with the successful amplification of this small amount of target. Another possible explanation is the difference in mutant-specific primer sequences. Although the design of primers and probe in these two reports is very similar in terms of concept and locations of the sequences, Gorello et al. used sense forward primers as mutant-specific primers, whereas ours were mutant-specific anti-sense reverse primers. The sequences of the other primer and probe were also different. It is possible that these trivial differences caused delicate changes in efficiency of annealing and amplification when the target number was very low.
In this study, we prove that NPM1 mutation is very stable in leukemia cells during a long-term follow-up period. All patients with true relapse presented detectable signals by the real-time PCR, indicating the same NPM1 mutations persisted at relapse. On the other hand, patient No. 15 (Group 3 in Supplementary  Figure 1 ) developed a second unrelated leukemia 56 months after the initial diagnosis of AML; the malignant cells contained new clonal chromosomal abnormalities but were devoid of NPM1 mutation, so reasonably could not be detected by our method (Patient No. 63 in our previous study 15 ). We did not include flow cytometry as a tool in MRD detection in this retrospective study. Given the wide use of multicolor flow cytometry in MRD monitoring in leukemia, it is interesting to see the correlation of these two methods in this specific group of patients.
